NASDAQ:MREO

Mereo Biopharma Group Stock Insider Trading

Healthcare > Biotechnology

Buy MREO

*Your capital is at risk

$0.334

-0.0052 (-1.53%)

At Close: Jun 03, 2026

Mereo Biopharma Group Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 28.10. In total, the insiders bought 10.06M and sold 624.26K MREO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	28.10
● Buy	10.06M shares
● Sell	624.26K shares
76% Buy Activity Moderate Negative Correlation
Buy Signal Medium Confidence Feb 02, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 28.1. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (76% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 13, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Hughes-wilson Alexandra See Remarks	Officer	84 008 Value: $354.6K
Sep 13, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Hughes-wilson Alexandra See Remarks	Officer	16 304 Value: $68.8K
Sep 13, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Fox Christine Ann Chief Financial Officer	C-Suite Officer	19 158 Value: $80.9K
Sep 13, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Sermon Charles General Counsel	Officer	20 946 Value: $88.4K
Sep 13, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Lewicki John A. Chief Scientific Officer	Officer	10 937 Value: $46.2K
Sep 13, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Scots-knight Denise Chief Executive Officer	CEO / President	60 046 Value: $253.5K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Scots-knight Denise Chief Executive Officer	CEO / President	28 611 Value: $128.0K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Lewicki John A. Chief Scientific Officer	Officer	5 212 Value: $23.3K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Sermon Charles General Counsel	Officer	9 980 Value: $44.6K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Fox Christine Ann Chief Financial Officer	C-Suite Officer	9 128 Value: $40.8K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Hughes-wilson Alexandra See Remarks	Officer	7 769 Value: $34.7K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Hughes-wilson Alexandra See Remarks	Officer	40 029 Value: $179.0K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Hughes-wilson Alexandra See Remarks	Officer	40 029 Value: $179.0K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Hughes-wilson Alexandra See Remarks	Officer	7 769 Value: $34.7K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Fox Christine Ann Chief Financial Officer	C-Suite Officer	9 128 Value: $40.8K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Sermon Charles General Counsel	Officer	9 980 Value: $44.6K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Lewicki John A. Chief Scientific Officer	Officer	5 212 Value: $23.3K
Sep 12, 2024 Sell	American Depositary Shares representing Ordinary Shares S-Sale	Scots-knight Denise Chief Executive Officer	CEO / President	28 611 Value: $128.0K
Sep 11, 2024 Buy	American Depositary Shares representing Ordinary Shares M-Exempt	Sermon Charles General Counsel	Officer	65 600 Value: $305.7K
Sep 11, 2024 Buy	Performance Based Restricted Stock Unit M-Exempt	Sermon Charles General Counsel	Officer	65 600 Value: $305.7K
Sep 11, 2024 Buy	American Depositary Shares representing Ordinary Shares M-Exempt	Fox Christine Ann Chief Financial Officer	C-Suite Officer	60 000 Value: $279.6K
Sep 11, 2024 Buy	Performance Based Restricted Stock Unit M-Exempt	Fox Christine Ann Chief Financial Officer	C-Suite Officer	60 000 Value: $279.6K
Sep 11, 2024 Buy	Share Options (Right to buy) M-Exempt	Hughes-wilson Alexandra See Remarks	Officer	75 000 Value: $75.8K
Sep 11, 2024 Buy	Share Options (Right to buy) M-Exempt	Hughes-wilson Alexandra See Remarks	Officer	93 333 Value: $130.7K
Sep 11, 2024 Buy	Performance Based Restricted Stock Unit M-Exempt	Hughes-wilson Alexandra See Remarks	Officer	40 000 Value: $186.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MEREO BIOPHARMA GROUP PLC

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase ...

Read Full Profile Here